RenCa-IL2 Cells

RenCa-IL2 is a genetically modified variant of the RenCa cell line, a murine renal adenocarcinoma cell line. This particular modification involves the stable transfection of the gene encoding for interleukin-2 (IL-2), a cytokine critical in the regulation of white blood cells that are crucial for the immune system. The IL-2 gene has been introduced into the RenCa cells to study the effects of IL-2 expression on tumor growth, immune cell recruitment, and the efficacy of immunotherapeutic strategies in a controlled experimental setting. Originally derived from renal carcinoma found in Balb/c mice, RenCa cells are used to explore cancer immunology and therapy approaches, particularly in understanding how tumors evade the immune system and how these defenses can be counteracted. The introduction of IL-2 into RenCa cells facilitates research into the role of this cytokine in modulating the tumor microenvironment, potentially enhancing the recruitment and activation of T cells and natural killer (NK) cells at the tumor site. This is particularly significant in the context of developing more effective cancer immunotherapies. Studies using the RenCa-IL2 cell line can contribute valuable insights into the mechanisms through which IL-2 may promote anti-tumor immune responses, thus serving as a model for the assessment of new cancer treatments that use cytokines to stimulate the immune response. Moreover, the RenCa-IL2 cell line is useful for evaluating the dynamics of immune cell interaction within the tumor milieu, providing a valuable tool for preclinical testing of biologic relevance and therapeutic potential.